Search clinical trials for: Nilotinib

Total 2984 results

University of Alabama at Birmingham
OSI Pharmaceuticals

Terminated

7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients

Pancreatic Cancer

United States
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
SCRI Development Innovations, LLC
GlaxoSmithKline; OSI Pharmaceuticals

Completed

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Non Small Cell Lung Cancer

United States
Bristol-Myers Squibb

Completed

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Non Small Cell Lung Cancer

Korea, Republic of, Taiwan, United States, Spain, France, Argentina, Canada, Poland
OSI Pharmaceuticals

Completed

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT)

Non-small Cell Lung Cancer

United States, Hungary, Spain, Taiwan, Korea, Republic of, Italy, United Kingdom, Canada, Australia, Belgium, Germany, Austria, Poland, Romania, Argentina, France, Czech Republic, Greece, Russian Federation
Michael Prados
National Cancer Institute (NCI); Genentech, Inc.

Terminated

Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Adult Brain Tumors

United States
NCIC Clinical Trials Group

Completed

Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Canada
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Non-Small-Cell Lung Cancer

Japan
OSI Pharmaceuticals
Canadian Cancer Trials Group

Completed

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Carcinoma, Non-small-cell Lung

Canada, United States, Australia, Singapore, Israel, China, Argentina, Germany, Sweden, Brazil, Chile, Greece, Mexico, New Zealand, Romania, South Africa, Thailand
Hoffmann-La Roche

Completed

A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Non-Squamous Non-Small Cell Lung Cancer

United Kingdom
Genentech, Inc.

Completed

A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy

Breast Cancer
Genentech, Inc.

Completed

A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)

Glioblastoma
Agennix

Completed

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

Lung Cancer

United States, Canada, Chile
M.D. Anderson Cancer Center
OSI Pharmaceuticals

Terminated

Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

Breast Cancer

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Advanced Solid Tumors

United States, United Kingdom
Shanghai Chest Hospital
Guangdong Provincial People's Hospital; Shanghai Pulmonary Hospital, Shanghai...

Temporarily not available

Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy

Non-small Cell Lung Cancer
Nanfang Hospital of Southern Medical University

Unknown

Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer

NSCLC

China
Kadmon Corporation, LLC

Terminated

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States
Hunan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Hunan Provincial People's...

Unknown

Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer

Non-small Cell Lung Cancer

China
OSI Pharmaceuticals

Completed

A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

Advanced Solid Tumors

United States, United Kingdom
University of Kansas Medical Center
Genentech, Inc.

Unknown

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

Breast Cancer

United States
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers

United States, Netherlands
SCRI Development Innovations, LLC
Bayer; OSI Pharmaceuticals

Completed

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib

Non-Small Cell Lung Cancer

United States
Taipei Veterans General Hospital, Taiwan

Unknown

The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib

Metastatic Pancreatic Cancer

Taiwan
Sanofi

Completed

Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors

Cancer | Non-Small Cell Lung Cancer

United States
Lung Cancer Group Cologne

Unknown

Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC) (ERLOPET)

Carcinoma, Non-Small-Cell Lung

Germany
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma

Malignant Brain Tumor | Brain Stem Glioma,

France
Hunan Cancer Hospital

Not yet recruiting

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Melanoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Thyroid Neoplasms

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

Medullary Thyroid Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Jinglong Chen

Recruiting

Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC

Hepatocellular Carcinoma

China
First Affiliated Hospital Xi'an Jiaotong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence (ALTER-H-004)

Hepatocellular Carcinoma | Anlotinib | TACE

China
The First Affiliated Hospital of Soochow University

Recruiting

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

CML, Chronic Phase; TKI

China
Shanghai Zhongshan Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors (FAITH)

Hepatocellular Carcinoma

China
Massachusetts Institute of Technology
Massachusetts General Hospital

Not yet recruiting

Investigating the Effects of Cannabidiol on Social Anxiety Disorder (CAN-SAD)

Phobia, Social

United States
Zhejiang Cancer Hospital

Not yet recruiting

A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC

Small Cell Lung Cancer Extensive Stage
Galapagos NV
Gilead Sciences

Completed

Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis (MANTA-RAy)

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis | Non-Radiographical Axial Spondyloarthritis

Bulgaria, Ukraine, Poland, Estonia, Czechia, Georgia, Latvia, Spain
Boundless Bio

Recruiting

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications (POTENTIATE)

Breast Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Liposarcoma | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Adenocarcinoma

United States
Daiichi Sankyo, Inc.

Completed

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

NSCLC (Advanced Non-small Cell Lung Cancer)

Ukraine, United Kingdom, United States, Bulgaria, Belgium, Germany, Hungary, Austria, Italy, Israel, Lithuania, Romania, Slovenia
Daiichi Sankyo, Inc.

Completed

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, India, Germany
Novartis Pharmaceuticals

Terminated

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Non-Small Cell Lung Cancer

Italy, Singapore, Spain, Germany, Korea, Republic of, United States, Belgium, France, Netherlands, Japan
Incyte Corporation

Withdrawn

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Solid Tumors and Hematologic Malignancy | NSCLC (Non-small Cell Lung Carcinoma)

United States
Kansas City Veteran Affairs Medical Center

Unknown

Erlotinib in Treating Patients With Barrett Esophagus

Esophageal Cancer | Precancerous Condition

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Sanofi

Completed

Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors

Cancer | Non-small Cell Lung Cancer

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

NSCLC

United States
Xijing Hospital

Not yet recruiting

An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC

Gastric Cancer

China
BerGenBio ASA

Completed

A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Patrick Joseph Loehrer Sr.
Exelixis

Terminated

Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma Metastatic

United States

3

Subscribe